Humanigen Inc (HGENQ)

[cowtown jay]

In terms of why I think our pending recall of loaned shares will cause a more significant short squeeze than our first one did, I listed the LIVE-AIR, PREACH-M, RATinG, and the Mayo Clinic-sponsored trial in CAR-T, that could lead to the authorization or approval of lenz. Those were the trials Humanigen highlighted in their last 10-Q. Success in those trials could entice sustained buying interest in Humanigen's stock.

But management also mentioned partnerships and a possible business combination, without going into further detail. I have voiced my opinion that Novavax may be a candidate for a relationship with Humanigen, and noted the covid opportunity for both companies working together.

"Novavax is projecting 30-35M covid vaccinations in the US this 2023-2024 period.

see slide 17

https://www.sec.gov/Archives/edgar/data/1000694/000110465924002100/tm242356d1_ex99-1.htm

If lenz is used as an adjuvant, or is used to enhance Novavax's Matrix-M saponin compound, that would greatly expand the market for lenz as a prophylaxis. But, if lenz is also used in the Combined Influenza Covid (CIC) vaccine, for which they have outlined a faster path forward in bringing to market (slide 14), then that could open a huge new market for lenz."

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173606511

But in addition for lenz to be used as a covid therapeutic, a covid prophylaxis, a CMML preventative, and to enhance bone marrow transplant, and CAR-T enhancement, Novavax mentions the following in regards to their effort to fight malaria.

Malaria "Kills 630,000 people/year, incl ~ 1,300 children/day."

see slide 12 of their presentation linked above.

Is this an additional opportunity for lenz? It seems to me that it is.

"Cytokine-modulating strategies may represent a promising modern approach in disease management. In this review, we discuss the host immune response in malaria, analyzing the latest studies on the roles of pro- and anti-inflammatory cytokines."

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8592744/

I have a long-standing, pro-Novavax bias. But it seems to me that the synergies of these two companies working together hold fantastic potential.